Status:
COMPLETED
Carbapenemase-Producing Organism and Vancomycin-Resistant Enterococcus Management
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Becton, Dickinson and Company
Conditions:
Multidrug-resistant Bacteria Screening
Eligibility:
All Genders
18+ years
Brief Summary
Emergence of vancomycin-resistant enterococci (VRE) and carbapenemase-producing enterobacteria (CPE) is nowadays a major public health concern worldwide. VRE and CPE are referred to as Emerging eXtens...
Detailed Description
Carbapenemases, with versatile hydrolytic capacity against β-lactams, are now an important cause of resistance of Gram-negative bacteria. Furthermore, they are often resistant to a wide-range of antim...
Eligibility Criteria
Inclusion
- Anybody coming in the CHUGA with at least one criteria of eXDR screening:
- Hospitalized patients at least two times within the previous year
- Patient transferred from another hospital
- Patient transferred from nursing home
- Patient with a history of hospitalization abroad (foreign countries) within the previous year
- Contact patient = patient exposed to an eXDR bacteria carrier
- eXDR carrier
Exclusion
- Refusal to participate to the study. Opposition of the patients to the use of their personal data.
- Refusal of rectal swab
Key Trial Info
Start Date :
February 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
3921 Patients enrolled
Trial Details
Trial ID
NCT05200546
Start Date
February 18 2022
End Date
March 31 2023
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Grenoble_Alpes UniversityHospital
Grenoble, France, 38043